Baxalta Gmbh

The State University of New York

Brookhaven Science Associates, Lcc

Baxter International Inc.

Baxter Healthcare Sa

Takeda Pharmaceuticals International Ag

Maria O'Rourke

Ian Livey

Michael Schwendinger

Brian A Crowe

John J Dunn

Benjamin J Luft

Ian Dr Livey

Benjamiin J Luft

The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety ofgenospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.

Chimeric OspA genes, proteins and methods of use thereof

Chimeric OspA proteins and methods of use thereof

Chimeric OspA genes, proteins, and methods of use thereof

The invention relates to the development of chimeric OpsA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety ofgenospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.

Growing community of inventors

Wiener Neudorf, Austria

Maria O'Rourke